ValenzaBio is a privately held, best-in-class biologics company with three differentiated product candidates and multiple additional discovery programs. Current product candidates are being developed for dermatologic, ophthalmic, and renal indications, and our hope is to launch our first medicine as soon as 2026.
Our product candidates utilize well-understood mechanisms of action, which minimizes clinical risk, and also feature biochemical properties that may make them superior to currently available therapies.
We’re using proven methods to develop medicines that provide true advantages to doctors and patients—and we’d love your help in fulfilling that mission! It’s an exciting time to be part of our company as we grow and advance our assets into the clinic.
Check out our current opportunities at the link below—or get in touch! We look forward to hearing from you.
Biologics company developing first-in-class monoclonal antibody (mAb) therapies
Multiple product candidates from discovery to Phase 2
VB421, anti-IGF-R1 mAb for thyroid eye disease
VB119, anti-CD-19 mAb for membranous neuropathy
VB517, anti-c-Kit mAb for chronic urticaria
Generous salary and benefits packages
GET IN TOUCH
6701 Democracy Blvd.
Bethesda, MD 20817